Ten large-cap stocks experienced significant declines during the week of February 16-20, 2026. Genuine Parts Company led losses with a 19.51% drop following worse-than-expected Q4 results and downward EPS guidance. Other major decliners included Blue Owl Capital (14.07%), Okta (12.86%), Flutter Entertainment (11.86%), and BridgeBio Pharma (11.43%), driven by analyst downgrades, disappointing earnings, and tender offer announcements.

BridgeBio Pharma's compensation committee approved equity grants of 76,701 restricted stock units to 34 new employees on February 12, 2026. The grants vest over four years with one-fourth vesting after one year and the remainder vesting quarterly thereafter, subject to continued employment.

BridgeBio Pharma announced positive Phase 3 trial results for infigratinib in treating achondroplasia (dwarfism) in children, showing superior annualized height velocity compared to placebo. The company plans to submit FDA and regulatory applications in the second half of 2026. The stock surged 6.92% to $78.41, nearing its 52-week high.

The biotech sector rebounded strongly in 2025 as M&A activity surged, becoming a stabilizing force for small and mid-cap companies. With 57% of biopharma acquisitions involving smaller firms and $30.9 billion in deals, investor sentiment shifted from GLP-1 drugs toward cancer and autoimmune disease treatments, particularly next-generation CAR-T therapies. Looking ahead to 2026, analysts expect continued M&A activity and strategic partnerships, though risks remain including FDA staff turnover and an 'IPO air pocket' from the 2023-2024 downturn.

BridgeBio Pharma presented data from the ATTRibute-CM study showing acoramidis significantly reduces all-cause mortality in variant ATTR-CM populations, with a 69% risk reduction in mortality for patients with the V142I genetic variant.

The National Advertising Division will refer BridgeBio Pharma to government agencies after the company failed to participate in an NAD inquiry regarding claims about its Attruby medication's superiority over Pfizer's Vyndamax.

BridgeBio Pharma announced successful Phase 3 trial results for BBP-418, a potential treatment for limb-girdle muscular dystrophy type 2I/R9, showing significant improvements in muscle function, glycosylation, and reduced muscle damage markers.

BridgeBio Pharma presented data from the ATTRibute-CM study showing acoramidis reduces cardiovascular outcomes in ATTR-CM patients, with significant risk reduction observed as early as the first month of treatment and sustained through 30 months.

BridgeBio's encaleret demonstrated promising results in a Phase 2 study for post-surgical hypoparathyroidism, with 80% of participants achieving normal blood and urine calcium levels within 5 days of treatment, leading to plans for a registrational clinical study in 2026.

BridgeBio Pharma presented data from the ATTRibute-CM open label extension study showing acoramidis reduced cardiovascular mortality by 44% in ATTR-CM patients over 42 months, demonstrating potential long-term clinical benefits for treating transthyretin amyloid cardiomyopathy.

Helix Acquisition Corp. II announced retaining approximately $120 million in its trust account, representing over 60% of cash, in connection with a business combination with BridgeBio Oncology Therapeutics. The transaction is expected to raise $382 million in gross proceeds, including $261 million from a private placement.

The global KRAS inhibitors market is experiencing significant growth, with four approved drugs targeting KRAS mutations in cancers like lung, colorectal, and pancreatic. Over 80 drugs are in clinical trials, with promising developments in targeted cancer therapies.